MitoRx Therapeutics Limited, a platform biotech company developing novel mitochondrial-targeted persulfide modifiers, has appointed Xavier Jacq as Chief Scientific Officer (CSO).

“Welcoming Xavier to MitoRx cements our position as the leading biotech company developing mitochondrial-targeted therapeutics,” said Jon Rees, CEO, MitoRx.

Experience

Jacq is a scientist with extensive experience in small molecule drug development and mitochondrial biology. He was most recently CSO at Moa Technologies in Oxford. Previously, he held scientific leadership positions at Almac and Mission Therapeutics, and project leadership positions at Kudos and Sanofi. He has been a company founder, helping raise investment, building labs and drug discovery teams from scratch, and helping companies successfully exit through acquisition.

The new CSO significantly strengthens the MitoRx team as it builds towards clinical candidate nomination in its lead indication of the treatment of obesity and also develops a pipeline of discrete novel persulfide modifiers for a range of degenerative diseases.

“MitoRx is developing an innovative technology to restore mitochondrial metabolic pathways that are suppressed in a number of pathologies and in ageing. The prospect of being able to contribute to restoring metabolic function for patients with unmet medical needs is such an exciting opportunity that I had to join,” said Xavier Jacq. “We now have the potential to make a significant difference for a large number of patients with degenerative diseases.”